DSIP vs ARA-290
Both DSIP and ARA-290 are used for neuroprotection. Here's how their evidence, dosing, and regulatory status actually compare.
DSIP
Evidence CDelta Sleep-Inducing Peptide
A nonapeptide originally isolated from rabbit blood after EEG-defined slow-wave sleep induction. Inconsistent human evidence for sleep but explored for stress and analgesia.
View full DSIP profile →ARA-290
Evidence BARA-290 (Cibinetide)
An 11-amino-acid peptide derived from the helix-B region of erythropoietin. Activates the tissue-protective receptor without erythropoietic side effects. Investigated for neuropathy and inflammation.
View full ARA-290 profile →Side-by-Side
| Attribute | DSIP | ARA-290 |
|---|---|---|
| Evidence Grade | C | B |
| FDA Status | Not FDA-approved — research compound | Not FDA-approved — Phase 2/3 trials for sarcoidosis-associated small fiber neuropathy |
| Typical Dose | 100–300 mcg before bed (subcutaneous) | Trial range: 1–4 mg subcutaneous daily |
| Clinics Indexed | 38 | 9 |
| Categories | sleep, neuroprotection | anti-inflammatory, neuroprotection |
Key reported benefits — DSIP
- ✓Slow-wave-sleep signals (preclinical)
- ✓Stress/cortisol modulation
- ✓Possible analgesic effect
Key reported benefits — ARA-290
- ✓Small-fiber neuropathy improvement
- ✓Anti-inflammatory
- ✓No erythrocytosis
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.